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S U M M A R Y
Objectives: To identify the age- and sex-speciﬁc antimicrobial susceptibility patterns of Gram-negative
bacteria (GNB) in outpatient febrile urinary tract infections (UTIs) in Korea.
Methods: A total 2262 consecutive samples collected from patients aged 1–101 years with febrile UTIs,
during the period January 2012 to December 2014, were analyzed in this multicentre, retrospective
cohort study.
Results: The sensitivities to cefotaxime and cefoxitin were over 85% for females but under 75% for males.
Sex played an important role in the susceptibility of GNB to cefotaxime (p < 0.001) and cefoxitin
(p < 0.001). The sensitivity to ciproﬂoxacin (age >20 years) was under 75% in both sexes, and was not
inﬂuenced by sex (p = 0.204). Age distributions of the incidences of resistance to cefotaxime, cefoxitin,
and ciproﬂoxacin (age >20 years) were similar to the age distribution of the incidence of GNB, which
indicates that the resistance patterns to these drugs were not affected by age (Kolmogorov–Smirnov test,
female/male: p = 0.927/p = 0.509, p = 0.193/p = 0.911, and p = 0.077/p = 0.999, respectively).
Conclusions: Age is not a considerable factor in determining the antibiotic resistance in febrile UTIs.
Ciproﬂoxacin should be withheld from both sexes until culture results indicate its use. Second- or third-
generation cephalosporins such as cefoxitin and cefotaxime can be used empirically only in females.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The selection of empirical antibiotics is of great importance in
the management of febrile urinary tract infections (UTIs).
According to international guidelines, ﬂuoroquinolones, second-
generation cephalosporins, third-generation cephalosporins, and
co-trimoxazole are designated empirical antimicrobials for UTIs,1,2
unless the resistance rate to community-dwelling Escherichia coli is
over 20%. Recent guidelines for the treatment of UTIs in Korea are
similar to international guidelines.3 However, recent data from* Corresponding author. Tel.: +82 31 249 7470; fax: +82 31 253 0949.
E-mail address: lee.seungju@gmail.com (S.-j. Lee).
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1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Korea have shown that, currently, only second- and third-
generation cephalosporins are appropriate empirical antibiotics
for community-acquired UTIs in adult females.4 Furthermore,
clinical susceptibility data are scarce regarding febrile UTIs,
including UTIs in males, in Korea. Data (n = 115) reported in
2008 showed that the sensitivities of pathogens to second- and
third-generation cephalosporins in acute prostatitis were 82.0%
and 82.5%, respectively.5 In addition, susceptibility data are lacking
for all age groups, as well as both sexes, for the outpatient setting.
Several studies have reported that age and/or sex could be risk
factors for emerging drug resistance in outpatient UTIs.6,7
Therefore, urine samples should be cultured before the adminis-
tration of antimicrobials, and clinicians should consider treating
high-risk groups (speciﬁc age or sex groups) empirically with theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Patient baseline characteristics and microorganisms isolated from 2262 UTIsa
Total(N = 2262) Female
(n = 1538)
Male
(n = 724)
Age (years) 48.59  26.63 53.13  22.41 38.93  31.82
Diabetes mellitus (%) 336 (14.9) 213 (13.8) 123 (17.0)
Urinary catheter (%) 67 (3.0) 16 (1.0) 51 (7.0)
Exposure to antibiotics (%) 654 (28.9) 464 (30.2) 190 (26.2)
Escherichia coli 1465 (64.8) 1131 (73.5) 334 (46.1)
Klebsiella pneumoniae 138 (6.1) 82 (5.3) 56 (7.7)
Pseudomonas aeruginosa 63 (2.8) 9 (0.6) 54 (7.5)
Proteus mirabilis 71 (3.1) 37 (2.4) 34 (5.0)
Enterobacter aerogenes 46 (2.0) 18 (1.2) 28 (3.9)
Enterobacter cloacae 32 (1.4) 14 (0.9) 18 (2.5)
Citrobacter freundii 20 (0.9) 14 (0.9) 6 (0.8)
Other Gram-negative
bacteria
61 (2.7) 23 (1.5) 38 (5.2)
Total Gram-negative
bacteria
1896 (83.8) 1328 (86.3) 568 (78.5)
Enterococcus faecalis 145 (6.4) 70 (4.6) 75 (10.4)
Enterococcus faecium 50 (2.2) 25 (1.6) 25 (3.5)
Streptococcus agalactiae 33 (1.5) 31 (2.0) 2 (0.3)
Staphylococcus aureus 43 (1.9) 29 (1.9) 14 (1.9)
Other Gram-positive
bacteria
79 (3.5) 41 (2.7) 38 (5.2)
Total Gram-positive
bacteria
350 (15.5) 196 (12.7) 154 (21.3)
Fungal infection 16 (0.7) 14 (0.9) 2 (0.3)
UTI, urinary tract infection.
a Age is presented as the mean  standard deviation value; other data are
presented as the number and frequency (%).
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the outpatient setting would facilitate the appropriate selection of
empirical agents for the treatment of UTIs.8 Hence, antimicrobial
susceptibility data from an outpatient setting, with consideration
of age and sex, are presented herein. Furthermore, it was
determined whether age and/or sex could impact the emergence
of drug resistance.
2. Materials and methods
2.1. Data collection
The present study was ﬁrst approved by a central ethics
committee (Catholic Medical Centre, The Catholic University of
Korea College of Medicine, Seoul, Korea; No. XC12RIMI0018 V,
XC14RIMI0109 V) and then approved by the respective local ethics
committees. This was a multicentre, retrospective cohort study.
UTIs were identiﬁed by positive specimens in a microbiology
laboratory, and a chart review was performed to differentiate
febrile UTIs. The data were collected from three teaching hospitals
with 600–1300 beds in the capital region of Korea (Seoul and
Gyeonggi) and three other teaching hospitals with 300–1000 beds
located in metropolitan areas (Daejeon, Busan, and Incheon), using
a web-based electronic system in which the data could be shared
among all of the institutes. A central ofﬁce managed all of the
electronically recorded data.
2.2. Study population and design
Any UTI patient, regardless of age or sex, with a clinical and
microbiological diagnosis of a UTI from January 2012 to December
2014, was eligible for the study. All patients with UTIs who were
included in the study presented the following characteristics: (1)
evidence of bacteriuria (104 CFU/ml) in the midstream urine; (2)
fever (tympanic membrane temperature >37.8 8C);9 (3) 5 white
blood cells per high-power ﬁeld in the urine; and (4) one or more of
the following symptoms/signs: dysuria, urgency, frequency, supra-
pubic pain, perineal pain, tenderness of prostate during digital
rectal examination, or costovertebral angle tenderness upon
percussion. Only cases in which a urine specimen had been
cultured before antimicrobials were administered were included.
Furthermore, only outpatient UTIs were included; inpatient UTIs
were excluded. For the present study, an outpatient UTI was deﬁned
as a case in which the patient had visited an outpatient clinic due to
a UTI, or symptoms and signs of a UTI were detected within 48 h of
hospitalization. Successive cultures from the same patient were
excluded to avoid data duplication during the treatment period, and
recurrent UTIs were excluded because they could negatively or
positively inﬂuence the susceptibility data. Thus, individual
patients were not included in the study multiple times. Finally,
patients who had bladder augmented with intestine, intestinal
neobladder, or any urinary-intestinal ﬁstulas were also excluded.
Only patients who had had indwelling urethral catheters for
more than 7 days were deﬁned as having catheter-associated UTIs.
The administration of antimicrobials within the previous 3 months
was classiﬁed as exposure to antibiotics.
The sensitive automatic MicroScan identiﬁcation system (Micro-
Scan; Baxter Diagnostics, Inc., West Sacramento, CA, USA) was used
to identify the subject bacteria, and minimal inhibitory concentra-
tions (MICs) were measured using the broth microdilution method.
MICs were obtained for the following antibiotics: amikacin,
ampicillin, amoxicillin/clavulanic acid, cefoxitin, cefotaxime, cefta-
zidime, ciproﬂoxacin, imipenem, piperacillin/tazobactam, and co-
trimoxazole. A sensitive/intermediate/resistant (SIR) interpretation
similar to that used in previous studies was used for the data report,
to obtain a simple description and for easy comparison;10–13however, reporting the MICs would have improved the monitoring
of dynamic and subtle changes in the antimicrobial susceptibilities.
The standard Clinical and Laboratory Standards Institute (CLSI)
guidelines were applied to set the MIC breakpoints.
2.3. Statistical analysis
The Kolmogorov–Smirnov test was used to assess the
differences in age distribution of the incidence of UTIs according
to the age distribution. The Chi-square test or Fisher’s exact test
was used for the univariate analysis to assess the potential risk
factors for resistance to each antimicrobial agent. Variables with a
signiﬁcant p-value (p < 0.05) were selected for inclusion in the
multivariate analysis. The logistic regression test was used for the
multivariate analysis (non-selection). Each statistical method is
also summarized in brief in the footnotes to the corresponding
table.
3. Results
E. coli was the most frequently isolated bacterium in both sexes;
however, E. coli was present in only 46.1% of male outpatient
febrile UTIs, but was present in 73.5% of female outpatient febrile
UTIs. Klebsiella pneumoniae, the second most frequently isolated
Gram-negative bacterium, was present in 5.3% of female febrile
UTIs and 7.7% of male febrile UTIs. Among Gram-negative bacteria,
E. coli was present in 85.2% of female outpatient febrile UTIs,
whereas 58.8% of outpatient febrile UTIs in males were associated
with E. coli. Meanwhile, Gram-negative bacteria explained 86.3% of
female febrile UTIs and 78.5% of male febrile UTIs, which was more
representative of outpatient febrile UTIs than E. coli by itself
(Table 1). The antimicrobial susceptibilities of Gram-negative
bacteria as well as E. coli are presented in Figure 1 and Tables 2 and
3; the antimicrobial susceptibilities of Gram-negative bacteria
were sub-analyzed for three different age groups.
The susceptibility of Gram-negative bacteria to the vast
majority of antibiotics was greater in females (over 80%) than
Figure 1. Antimicrobial susceptibility patterns for the drugs tested in the present study. The name of each antibiotic is given at the top of each graph. The y-axis shows the
sensitivity (%) to the relevant antibiotic. The sensitivity of Gram-negative bacteria was sub-analyzed for three different age groups. The sensitivity of E. coli is provided at the
end of the x-axis.
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females, the sensitivity of Gram-negative bacteria was >85% to
third-generation cephalosporin (group 3a cephalosporin: cefotax-
ime) and second-generation cephalosporin (cephamycin: cefox-
itin), regardless of the patient’s underlying condition, whereas
susceptibility was < 80% in males . The sensitivity of Gram-
negative bacteria was >80% for amikacin and restricted antibioticsFigure 2. Age-speciﬁc distributions of incidences for Gram-negative febrile UTI in outpat
incidence of total Gram-negative UTIs in the two sexes were different (left graph: female;
of the incidences of Gram-negative UTIs and E. coli were not different in females (left g
Z = 0.656, p = 0.783. (C) Age distributions of the incidences of Gram-negative UTIs and E.
population); Kolmogorov–Smirnov Z = 0.556, p = 0.916.such as cefepime, piperacillin/tazobactam, and imipenem in both
sexes (Figure 1, Tables 2 and 3).
The mean patient age for the total study population was
48.59  26.63 years (Table 1). However, the mean age of patients with
UTIs was of no clinical importance considering the whole age
distribution, because the incidence of UTIs showed a bimodal age
distribution (Figure 2). The percentage of diabetes mellitus, indwellingients of both sexes. Each y-axis represents the incidence. (A) Age distributions of the
 right graph: male); Kolmogorov–Smirnov Z = 6.583, p < 0.001. (B) Age distributions
raph: total UTI population; right graph: E. coli population); Kolmogorov–Smirnov
 coli were not different in males (left graph: total UTI population; right graph: E. coli
Table 2
Antimicrobial susceptibilities of 1328 Gram-negative bacteria in female febrile UTI outpatientsa
E. coli % 1131/1328 (85.2) 81/106 (76.4) 530/607 (87.3) 520/615 (84.6) 1131/1131 (100.0)
Age GNB, all ages Young (<20 years) Middle (20–60 years) Old (>60 years) E. coli, all ages
AMK S 1294/1308 (98.9)
I 9/1308
R 5/1308
S 105/106 (99.1)
I 1/106
R 0/106
S 594/590 (99.0)
I 4/590
R 2/590
S 605/612 (98.9)
I 4/612
R 3/612
S 1120/1131 (99.0)
I 8/1131
R 3/1131
AMX S 361/1282 (28.2)
I 11/1282
R 910/1282
S 20/95 (21.1)
I 1/95
R 74/95
S 186/585 (31.8)
I 3/585
R 396/585
S 155/612 (25.3)
I 7/612
R 440/612
S 339/1118 (30.3)
I 9/1118
R 770/1118
AUG S 830/1101 (75.4)
I 167/1101
R 104/1101
S 42/71 (59.2)
I 12/71
R 17/71
S 385/506 (76.1)
I 79/506
R 42/506
S 403/524 (76.9)
I 76/524
R 45/524
S 743/960 (77.4)
I 156/960
R 61/960
CFX S 958/1104 (86.8)
I 63/1104
R 83/1104
S 64/72 (88.9)
I 2/72
R 6/72
S 450/507 (88.8)
I 20/507
R 37/507
S 444/525 (84.6)
I 41/525
R 40/525
S 809/961 (84.1)
I 105/961
R 47/961
CTX S 1130/1315 (85.9)
I 8/1315
R 177/1315
S 75/99 (75.8)
I 4/99
R 20/99
S 542/604 (89.7)
I 1/604
R 61/604
S 513/612 (83.8)
I 3/612
R 96/612
S 976/1120 (87.1)
I 2/1120
R 142/1120
CTZ S 1122/1304 (86.0)
I 10/1304
R 172/1304
S 85/106 (80.2)
I 1/106
R 20/106
S 524/588 (89.1)
I 5/588
R 59/588
S 513/610 (84.1)
I 4/610
R 93/610
S 974/1128 (86.3)
I 6/1128
R 145/1128
CFP S 1147/1308 (87.7)
I 0/1308
R 161/1308
S 92/106 (86.7)
I 0/106
R 14/106
S 534/591 (90.4)
I 0/591
R 57/591
S 521/611 (85.3)
I 0/611
R 90/611
S 983/1128 (87.1)
I 0/1128
R 142/1128
CP S 803/1298 (61.9)
I 39/1298
R 456/1298
S 81/97 (83.5)
I 1/97
R 15/97
S 380/588 (64.6)
I 12/588
R 196/588
S 342/613 (55.8)
I 26/613
R 245/613
S 650/1123 (57.9)
I 32/1123
R 433/1123
PT S 1239/1302 (95.2)
I 24/1302
R 39/1302
S 90/105 (85.7)
I 4/105
R 11/105
S 567/588 (96.4)
I 8/588
R 13/588
S 582/609 (95.6)
I 12/609
R 15/609
S 1087/1128 (96.4)
I 17/1128
R 24/1128
IMP S 1305/1309 (99.7)
I 0/1309
R 4/1309
S 105/106 (99.1)
I 0/106
R 1/106
S 590/591 (99.8)
I 0/591
R 1/591
S 610/612 (99.7)
I 0/612
R 2/612
S 1131/1131 (100.0)
I 0/1131
R 0/1131
CTMZ S 811/1307 (62.1)
I 0/1307
R 496/1307
S 66/106 (62.3)
I 0/106
R 40/106
S 375/591 (63.5)
I 0/591
R 216/591
S 365/610 (59.8)
I 0/610
R 240/610
S 682/1129 (60.4)
I 0/1129
R 447/1129
UTI, urinary tract infection; GNB, Gram-negative bacteria; S, susceptible; I, intermediate; R, resistant; AMK, amikacin; AMX, amoxicillin; AUG, amoxicillin/clavulanic acid;
CFX, cefoxitin; CTX, cefotaxime; CTZ, ceftazidime; CFP, cefepime; CP, ciproﬂoxacin; PT, piperacillin/tazobactam; IMP, imipenem; CTMZ, co-trimoxazole.
a For the reader’s convenience, percentages are presented in parenthesis only for the susceptible category.
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28.9%, respectively, in total febrile UTIs.
The age distribution of the incidence of total febrile Gram-
negative UTIs exhibited a bimodal peak for both sexes; however,
the age distributions of total outpatient febrile Gram-negative UTIs
differed by sex (Figure 2). Most febrile Gram-negative UTIs were
observed in the middle-age and older age groups in females,
whereas over one-third of male febrile Gram-negative UTIs were
found in the younger age group (Figure 2, Table 3). The age
distribution of E. coli was similar to that of the Gram-negative
bacteria for each sex (Figure 2).
When age was classiﬁed as young, middle, and old, suscepti-
bilities of Gram-negative UTIs to amoxicillin/clavulanic acid,
cefotaxime, and ciproﬂoxacin were seen to differ according to
the age distribution (Figure 1), but on statistical analysis, it was
found that only susceptibility to ciproﬂoxacin differed over the
entire age distribution (Figures 3 and 4) .
Susceptibility to ciproﬂoxacin was higher in the younger age
group than in the middle or old age group for both sexes
(Table 2 and 3, and Figure 4) . However, for patients aged >20
years, the age distribution of the incidence of resistance to
ciproﬂoxacin was similar to the age distribution of the incidence of
total Gram-negative UTIs in both sexes (for age >20 years:
Kolmogorov–Smirnov Z = 0.370, p = 0.999 in males; Kolmogorov–
Smirnov Z = 1.277, p = 0.077 in females), which indicated that the
resistance pattern for ciproﬂoxacin was not affected by age in adult
febrile Gram-negative UTIs. Antimicrobial resistance for cefoxitin,
cefotaxime, and amoxicillin/clavulanic acid also showed no
association with age (Figure 3 and 4) .A sub-analysis of potential risk factors for ciproﬂoxacin
resistance was performed for those aged < 20 years.
Tables 4 and 5 show the risk factors for resistance to cefoxitin,
cefotaxime, and ciproﬂoxacin . Regarding ﬂuoroquinolones (age
>20 years), only exposure to antibiotics was a risk factor for
selecting resistance, whereas sex, the presence of an indwelling
catheter (only signiﬁcantly associated with cefotaxime), and
exposure to antibiotics were predisposing factors for emerging
resistance of Gram-negative bacteria with the use of second- and
third-generation cephalosporins.
Among Gram-negative febrile UTIs, catheter-associated UTIs
were more frequently observed in males than in females, were
more closely related to exposure to antibiotics, and exhibited a
higher occurrence of infection caused by an atypical organism such
as Citrobacter species, Proteus mirabilis, Morganella morganii,
Enterobacter species, and Pseudomonas aeruginosa rather than E.
coli (Table 6).
4. Discussion
Interestingly, no differences in the age distribution between
Gram-negative febrile UTIs and febrile UTIs caused by second- and
third-generation cephalosporin-resistant organisms were found
for either sex, despite a difference in the age distribution between
the sexes. These ﬁndings suggest that age does not exert any
inﬂuence on the acquisition of resistance to second- and third-
generation cephalosporins .
Most Gram-negative UTIs were observed in the middle and
older age groups in females, whereas one-third of Gram-negative
Figure 3. Age distributions of the incidences of resistance to second- and third-generation cephalosporins. Each y-axis represents the incidence. The incidence of resistance to
second-generation cephalosporins (cefoxitin) was similar to the incidence of total Gram-negative UTIs across the different ages, which indicates that the resistance pattern to
cefoxitin was not affected by age (for females, Kolmogorov–Smirnov Z = 1.081, p = 0.193; for males, Kolmogorov–Smirnov Z = 0.561, p = 0.911). The incidence of resistance to
third-generation cephalosporins (cefotaxime) was similar to the incidence of total Gram-negative UTIs across the different ages, which indicates that the resistance pattern to
cefotaxime was not affected by age (for females, Kolmogorov–Smirnov Z = 0.546, p = 0.927; for males, Kolmogorov–Smirnov Z = 0.822, p = 0.509).
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Table 2 and 3). These features are very important when
considering the sensitivities of ﬂuoroquinolones in an entire
age group. Because ﬂuoroquinolones are relatively contra-
indicated in the younger age group,14 which results in the
susceptibility to ﬂuoroquinolones being preserved in this group
compared to the middle and older age groups (Figure 1 and 4, and
Table 2 and 3), the subsequent result is more indicative of the
sensitivity to ﬂuoroquinolones of Gram-negative UTIs in males
than of Gram-negative UTIs in females. Thus, it appears that
Gram-negative bacteria were more susceptible to ﬂuoroquino-
lones in male febrile UTIs than in female febrile UTIs. Therefore,
the conclusion that antimicrobial susceptibility could be affected
by age may not be accurate. If we consider the age group >20
years (potential users of these drugs), the susceptibilities to
ﬂuoroquinolones were not affected by age (Figure 4) or
inﬂuenced by sex (Table 5). Therefore, it is concluded that age
alone might not be a risk factor for ﬂuoroquinolone resistance, as
it was not a risk factor for cephalosporin resistance. Adam et al.
summarized antibiotic susceptibility regardless of the site of
infection and found that the susceptibility of E. coli to
ciproﬂoxacin was relatively higher in the younger age group
than in the middle and older age groups. These results are similar
to those presented herein, although they did not discuss any
reason for this phenomenon.15
The next step should be to identify whether exposure to
antibiotics, sex, and/or other possible conditions such as
diabetes mellitus and catheterization, affect the sensitivitiesof Gram-negative febrile UTIs to antibiotics. In the present
study, despite considering other possible conditions, exposure to
antibiotics was the most important risk factor for selecting
resistance to cefoxitin, cefotaxime, and ciproﬂoxacin in outpa-
tient febrile Gram-negative UTIs (Table 4 and 5). Considering
that these drugs are currently recommended empirical anti-
biotics and are the most frequently prescribed treatments in
Korea,16 a national strategy to reduce exposure to these
antibiotics should be developed.
Carson et al. demonstrated that the vast majority of men with a
UTI had underlying factors that impede bacteriological eradica-
tion.17 However, can it be said that the male sex alone is a risk
factor for selecting resistance? In the present study, considering
the total amount of Gram-negative bacteria, male sex was a risk
factor for selecting antimicrobial resistance with regard to second-
and third-generation cephalosporins; however, the proportion of E.
coli was different in the two sexes (Tables 1–3). McGregor et al.
collected data from primary care clinics in the USA and concluded
that differences in antimicrobial susceptibilities between sexes
were not of clinical signiﬁcance because the differences were
generally less than 5% in most of the tested antibiotics.18 In the
present study, Gram-negative bacteria exhibited lower sensitivity
in males than in females for the majority of the tested antibiotics,
except ciproﬂoxacin and co-trimoxazole; however, for E. coli-
related UTIs, the susceptibilities to most antibiotics exhibited a
difference within 5% between the sexes, except for cefotaxime,
which is a reason to consider other atypical Gram-negative
bacteria during the management of febrile UTIs, especially in
Table 3
Antimicrobial susceptibilities of 568 Gram-negative bacteria in male febrile UTI outpatientsa
E. coli % 334/568 (58.8) 129/233 (55.4) 73/127 (57.5) 132/208 (63.5) 334/334 (100.0)
Age GNB, all ages Young (<20 years) Middle (20–60 years) Old (>60 years) E. coli, all ages
AMK S 534/568 (94.0)
I 20/568
R 14/568
S 229/233 (98.3)
I 3/233
R 1/233
S 114/127 (89.8)
I 9/127
R 4/127
S 191/208 (91.8)
I 8/208
R 9/208
S 328/334 (98.2)
I 4/334
R 2/334
AMX S 122/490 (24.9)
I 126/490
R 242/490
S 34/201 (16.9)
I 4/201
R 163/201
S 32/109 (29.4)
I 46/109
R 31/109
S 56/180 (31.1)
I 76/180
R 48/180
S 110/324 (34.0)
I 70/324
R 144/324
AUG S 252/447 (56.4)
I 85/447
R 110/447
S 76/156 (48.7)
I 25/156
R 55/156
S 66/110 (60.0)
I 26/110
R 18/110
S 110/181 (60.8)
I 34/181
R 37/181
S 185/292 (63.4)
I 48/292
R 59/292
CFX S 325/435 (74.7)
I 39/435
R 71/435
S 64/156 (75.0)
I 7/156
R 32/156
S 74/105 (70.5)
I 16/105
R 15/105
S 134/174 (77.0)
I 16/174
R 24/174
S 249/292 (85.3)
I 13/292
R 30/292
CTX S 388/546 (71.1)
I 75/546
R 83/546
S 162/214 (75.7)
I 8/214
R 44/214
S 86/126 (68.3)
I 26/126
R 14/126
S 140/206 (68.0)
I 41/206
R 25/206
S 251/324 (77.5)
I 31/324
R 42/324
CTZ S 454/566 (80.2)
I 35/566
R 77/566
S 180/232 (77.6)
I 8/232
R 44/232
S 107/127 (84.3)
I 9/127
R 11/127
S 167/207 (80.7)
I 18/207
R 22/207
S 275/332 (82.8)
I 14/332
R 43/332
CFP S 469/566 (82.9)
I 31/566
R 66/566
S 199/232 (85.8)
I 2/232
R 31/232
S 104/127 (81.9)
I 9/127
R 14/127
S 166/207 (80.2)
I 20/207
R 21/207
S 276/332 (83.1)
I 13/332
R 43/332
CP S 403/546 (73.8)
I 65/546
R 78/546
S 190/214 (88.8)
I 4/214
R 20/214
S 78/125 (62.4)
I 26/125
R 21/125
S 134/207 (64.7)
I 35/207
R 37/207
S 231/325 (71.1)
I 38/325
R 56/325
PT S 491/566 (86.7)
I 20/566
R 55/566
S 200/233 (85.8)
I 4/233
R 29/233
S 107/126 (84.9)
I 7/126
R 12/126
S 184/207 (88.9)
I 9/207
R 14/207
S 308/334 (92.2)
I 4/334
R 21/334
IMP S 546/568 (96.1)
I 11/568
R 11/568
S 230/233 (98.7)
I 3/233
R 0/233
S 120/127 (94.5)
I 3/127
R 4/127
S 196/208 (94.2)
I 5/208
R 7/208
S 334/334 (100.0)
I 0/334
R 0/334
CTMZ S 376/557 (67.5)
I 60/557
R 121/557
S 162/229 (70.7)
I 0/229
R 67/229
S 82/123 (66.7)
I 20/123
R 21/123
S 129/205 (62.9)
I 40/205
R 33/205
S 228/334 (68.3)
I 31/334
R 75/334
UTI, urinary tract infection; GNB, Gram-negative bacteria; S, susceptible; I, intermediate; R, resistant; AMK, amikacin; AMX, amoxicillin; AUG, amoxicillin/clavulanic acid;
CFX, cefoxitin; CTX, cefotaxime; CTZ, ceftazidime; CFP, cefepime; CP, ciproﬂoxacin; PT, piperacillin/tazobactam; IMP, imipenem; CTMZ, co-trimoxazole.
a For the reader’s convenience, percentages are presented in parenthesis only for the susceptible category.
Table 4
Potential risk factors for cefoxitin and cefotaxime resistance in Gram-negative UTIs
Resistance to
cefoxitin for all ages
p-Valuea
OR, 95% CI
p-Valueb
OR, 95% CI
Resistance to
cefotaxime for all ages
p-Valuea
OR, 95% CI
p-Valueb
OR, 95% CI
Sex Male
110/435
Female
146/1104
<0.001
2.221, 1.683–2.931
<0.001
2.239, 1.676–2.992
Male
158/546
Female
185/1315
<0.001
2.487, 1.953–3.167
<0.001
2.593, 1.998–3.364
Diabetes mellitus Yes
47/244
No
209/1295
0.225
1.240, 0.873–1.761
– Yes
76/295
No
267/1566
0.001
1.688, 1.260–2.262
0.131
1.276, 0.930–1.751
Catheter Yes
18/46
No
238/1493
<0.001
3.390, 1.845–6.227
0.061
1.850, 0.972–3.520
Yes
29/56
No
314/1805
<0.001
5.100, 2.978–8.735
0.003
2.406, 1.336–4.331
Exposure to antibiotics Yes
100/395
No
156/1144
<0.001
2.364, 1.783–3.133
<0.001
2.412, 1.803–3.227
Yes
169/507
No
174/1354
<0.001
3.391, 2.657–4.327
<0.001
3.745, 2.897–3.364
UTI, urinary tract infection; OR, odds ratio; CI, conﬁdence interval.
a p-Value measured using the Chi-square test.
b p-Value measured using the logistic regression test (non-selection).
Table 5
Potential risk factors for ciproﬂoxacin resistance in Gram-negative UTIs
Resistance to
ciproﬂoxacin for all ages
p-Valuea
OR, 95% CI
p-Valueb
OR, 95% CI
Resistance to
ciproﬂoxacin for age >20
years
p-Valuea
OR, 95% CI
Sex Male
143/546
Female
495/1298
<0.001
0.576, 0.461–0.718
<0.001
0.547, 0.432–0.693
Male
119/332
Female
479/1201
0.204
0.842, 0.654–1.084
Diabetes mellitus Yes
125/297
No
513/1547
0.003
1.465, 1.137–1.887
0.135
1.230, 0.938–1.614
Yes
125/297
No
473/1236
0.233
1.172, 0.906–1.516
Catheter Yes
26/56
No
612/1788
0.064
1.665, 0.976–2.841
– Yes
26/56
No
572/1477
0.265
1.371, 0.803–2.342
Exposure to antibiotics Yes
283/496
No
355/1348
<0.001
3.716, 2.997–4.609
<0.001
3.601, 2.891–4.487
Yes
274/459
No
324/1074
<0.001
3.428, 2.731–4.304
UTI, urinary tract infection; OR, odds ratio; CI, conﬁdence interval.
a p-Value measured using the Chi-square test.
b p-Value measured using the logistic regression test (non-selection).
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Figure 4. Age distributions of the incidences of resistance to amoxicillin/clavulanic acid and ﬂuoroquinolones in Gram-negative bacteria. Each y-axis represents the incidence.
The age distribution of the incidence of resistance to ﬂuoroquinolones (ciproﬂoxacin) was different from the age distribution of the incidence of total Gram-negative UTIs,
which indicates that the resistance pattern to ciproﬂoxacin was affected by age (for females, Kolmogorov–Smirnov Z = 1.540, p = 0.017; for males, Kolmogorov–Smirnov
Z = 2.405, p < 0.001). Note that for patients >20 years of age, the age distribution of Gram-negative bacteria was not different from that of ﬂuoroquinolone resistance for
either sex (Kolmogorov–Smirnov Z = 0.370, p = 0.999 in males; Kolmogorov–Smirnov Z = 1.277, p = 0.077 in females). The age distribution of the incidence of resistance to
amoxicillin/clavulanic acid was similar to the age distribution of the incidence of total Gram-negative UTIs across the different ages, which indicates that the resistance
pattern to amoxicillin/clavulanic was not affected by age (for females, Kolmogorov–Smirnov Z = 0.881, p = 0.420; for males, Kolmogorov–Smirnov Z = 0.907, p = 0.383).
D.S. Lee et al. / International Journal of Infectious Diseases 51 (2016) 89–96 95males. Consequently, male sex has a minor effect on lowering the
susceptibility of E. coli but has a great effect on lowering the
susceptibility of Gram-negative bacteria by producing an increased
chance of atypical bacterial infection.
Outpatient data in Italy showed that 55.0% of UTIs and 62.6% of
Gram-negative UTIs in males were caused by E. coli, whereas E. coli
was found in 71.0% of UTIs and 77.5% of Gram-negative UTIs in
females.19 In the present study, only 46.1% of UTIs and 58.8% of
Gram-negative UTIs in males were caused by E. coli, whereas E. coli
was detected in 73.5% of UTIs and 85.2% of Gram-negative UTIs inTable 6
Features of catheter-associated UTIs in the Gram-negative UTIs
Catheterized Non-catheterized p-Valuea
OR, 95% CI
Sex
Male/female
42/14 526/1314 <0.001
7.494, 4.059–13.838
E. coli infection
Yes/no
26/30 1439/401 <0.001
0.242, 0.141–0.413
Exposure to
antibiotics
Yes/no
32/24 476/1364 <0.001
3.821, 2.228–6.553
UTI, urinary tract infection; OR, odds ratio; CI, conﬁdence interval.
a p-Values measured using the Chi-square test.females. Therefore, whether E. coli can accurately represent
antimicrobial susceptibility, especially in males, is difﬁcult to
assess. Physicians should be aware of regional Gram-negative
susceptibility data, as well as risk factors for antibiotic resistance,
prior to selecting the appropriate empirical antibiotics for
outpatient febrile UTIs in males, because the selection of an
appropriate drug can improve the prognosis, especially in critically
ill patients.20 Therefore, primary care physicians should select
empirical antibiotics carefully for males after determining whether
they have been exposed to antibiotics previously or have a history
of a recent urinary catheter. If this information is not conﬁrmed in
critically ill male outpatients with febrile UTIs, physicians should
not hesitate to use amikacin as a combination regimen or use
restricted antibiotics such as cefepime, piperacillin/tazobactam, or
carbapenems as empirical antibiotics, at least until the culture
report indicates the use of other antibiotics such as ﬂuoroquino-
lones or cephalosporins.
Clinicians should also take into account catheter-associated
UTIs. Although only 56 outpatients with catheter-related febrile
UTIs were included among the 1896 outpatient Gram-negative
febrile UTIs, the results conveyed an important message. In this
cohort, catheter-associated UTIs were seven times more common
in males than in females and were negatively associated with E. coli
infection (Table 6). A wide variety of infectious organisms may be
D.S. Lee et al. / International Journal of Infectious Diseases 51 (2016) 89–9696isolated from catheter-associated UTIs.21 In long-term indwelling
catheter patients, E. coli was isolated in only 18–35% of cases.
Instead, atypical Gram-negative bacteria were found in these
patients. In addition, increased antimicrobial resistance was found
in catheter-associated UTIs,22 which could be due in part to the
frequent exposure to antibiotics.
Research conducted in the Asia-Paciﬁc region showed the
variation in extended-spectrum beta-lactamase (ESBL)-producing
E. coli among countries; however, it was not clear whether the
isolates originated from inpatient or outpatient UTIs.23 Further-
more, although the study was multinational, the results were not
reported according to age, sex, or other underlying risk conditions;
therefore the results could not be applied directly to any country
within the Asia-Paciﬁc area. In that study, the general sensitivities
of Gram-negative bacteria to ciproﬂoxacin, cefoxitin, and cefotax-
ime were 51.4%, 74.2%, and 50.3%, respectively.23
Other studies have been conducted on outpatient UTIs. In India,
E. coli isolates from outpatient UTIs showed very high resistance
rates to second- and third-generation cephalosporins (55–85%),
and ESBL was detected in 34.4% of E. coli isolates.24 Although the
authors collected specimens from both sexes for all age groups (0–
80 years) and presented susceptibility data according to the
pathogen, they did not show the data by age or sex .24
The present authors have previously presented susceptibility
data for organisms causing UTIs in adult females in Korea .16 These
previous data were focused on E. coli in UTIs in adult females and
on comparing inpatient data with outpatient data; UTIs in males
were not discussed, and the age distribution was limited to a range
of 25 to 65 years. Although the age was different and the
underlying complicating factors such as catheterization and
previous exposure to antibiotics were not the same in the present
study and previous studies, the antimicrobial susceptibilities of
UTIs in female outpatients exhibited little decline in the present
study (2012–2014) compared to the previous data (2010–2011).
The present study describes the antimicrobial susceptibility
pattern of Gram-negative bacteria with respect to age and sex in
Korea. For the populations in which ﬂuoroquinolones were
applicable (age >20 years), neither age nor sex was found to be
a risk factor for emerging resistance in Gram-negative bacteria.
Instead, exposure to antibiotics was a conﬁrmed risk factor for
ﬂuoroquinolone resistance; however, the susceptibility of Gram-
negative bacteria to these drugs was noticeably lower than 70% in
this outpatient setting for both sexes, and physicians should not
consider the use of these drugs as empirical antibiotics in Korea
. With regard to cephalosporins, age was not a risk factor for
lowering antimicrobial susceptibility in Gram-negative febrile
UTIs; however, male sex and other factors such as exposure to
antibiotics and an indwelling urinary catheter were revealed to be
risk factors for the selection of antimicrobial resistance.
The important messages from the present study include the
following: (1) physicians should carefully choose an empirical
antibiotic agent(s) after considering hospital-related patient
histories including medication and catheterization, especially for
acute febrile UTIs in males; (2) age itself is not a considerable factor
for physicians when determining the antibiotics to use in febrile
UTIs; and (3) extensive efforts should be made to reduce the
misuse and abuse of antibiotics, and the unnecessary use of a
urinary catheter.
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